Business Context and Reporting Period
This Form 8-K is filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc.) on April 1, 2024. The report announces the issuance of a press release detailing financial results for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol RSLS.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
No material changes versus the prior comparable period are described in the text of this filing. The document serves solely as a notification that the annual results have been released.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of unusual items. It explicitly states that the information furnished pursuant to Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net income, cash position) by reviewing Exhibit 99.1 (Press Release dated April 1, 2024).
- Confirm the company name is ReShape Lifesciences Inc., as the input metadata referenced Vyome Holdings, Inc.
- Review the full press release for any forward-looking statements or updated guidance not included in this summary.
- Check the Nasdaq Capital Market for any trading halts or announcements related to the release of these results.